Phase 3 Study of VX-770 in Children Ages 6 to 11 With a Specific Type of Cystic Fibrosis Showed Profound Improvements in Lung Function (FEV1) and Other Measures of Disease Through 24 Weeks.

Extract

---

Phase 3 Study of VX-770 in Children Ages 6 to 11 With a Specific Type of Cystic Fibrosis Showed Profound Improvements in Lung Function (FEV1) and Other Measures of Disease Through 24 Weeks.

-Mean relative improvement in lung function of 17.4% and mean absolute improvement of 12.5% from baseline compared to placebo in children treated with VX-770-

- No discontinuations due to adverse events through 24 weeks -

-Vertex on track to submit regulatory applications for the approval of VX-770 in the U.S. and Europe in the second half of 2011 -

CAMBRIDGE, Mass. -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from a 24-week analysis of the ongoing Phase 3 ENVISION study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis (CF). ENVISION (n=52) was designed to evaluate VX-770 among children ages 6 to 11 w...

See the full content of this document

---